NCT07457255Completed
Late Endocrine and Metabolic Consequences After Childhood Brain Tumor Treatment
Late Endocrine and Metabolic Consequences of Treatment of Primary Brain Tumors in Childhood
Source: ClinicalTrials.gov · Last updated 9 Mar 2026
Brief summary (registry, in English)
This interventional study evaluates the late endocrine and metabolic consequences of treatment of primary brain tumors in childhood. Childhood brain tumor survivors are at increased risk of developing long-term complications such as hormonal deficiencies, obesity, impaired growth, dyslipidemia, and other metabolic disorders, which may significantly affect long-term health and quality of life. The aim of this study is to assess the prevalence and severity of endocrine and metabolic late effects in patients treated for brain tumors during childhood in Slovenia, and to identify associations with tumor localization, treatment modality, and physical performance. Participants undergo structured clinical follow-up examinations and targeted endocrine and metabolic assessments according to the study protocol. The results of this study may help identify individuals at increased risk and improve long-term follow-up strategies, prevention, and management of late treatment-related complications.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 18 Feb 2026
- Start date
- 1 Jan 2023
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Institute of Oncology Ljubljana
- Diseases
- Childhood cancers
- NCT number
- NCT07457255
What you commit to
- Study type: Interventional
- Participants enrolled: 12
- From 1 Jan 2023 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active malignant disease requiring ongoing oncological treatment
- Severe acute illness preventing participation in endocrine/metabolic evaluation
Other
- Inability to comply with study procedures or follow-up assessments
- Refusal or inability to provide informed consent
Who the study is looking for
- History of primary brain tumor diagnosed and treated in childhood
- Completed treatment for primary brain tumor (surgery and/or radiotherapy and/or chemotherapy)
- Patient is in follow-up care at the Institute of Oncology Ljubljana
- Availability for clinical endocrine and metabolic assessment
- Written informed consent provided by the participant or legal guardian (if applicable)
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Oncology Ljubljana Coordinator of this site? Confirm its status | Ljubljana | Slovenia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.